Total Payments
$16,206
2024 Payments
$4,842
Companies
4
Transactions
28
Medicare Patients
1,136
Medicare Billing
$66,902
Payment Breakdown by Category
Travel$8,309 (51.3%)
Consulting$3,710 (22.9%)
Research$3,639 (22.5%)
Food & Beverage$548.36 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $8,309 | 3 | 51.3% |
| Consulting Fee | $3,710 | 2 | 22.9% |
| Unspecified | $3,639 | 18 | 22.5% |
| Food and Beverage | $548.36 | 5 | 3.4% |
Payments by Type
General
$12,567
10 transactions
Research
$3,639
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cochlear Ltd | $7,142 | 1 | $0 (2018) |
| Advanced Bionics, LLC | $5,131 | 7 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,782 | 19 | $0 (2024) |
| MED-EL Corporation | $150.86 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,842 | 20 | Regeneron Pharmaceuticals, Inc. ($3,782) |
| 2023 | $150.86 | 1 | MED-EL Corporation ($150.86) |
| 2022 | $435.40 | 1 | Advanced Bionics, LLC ($435.40) |
| 2019 | $3,381 | 2 | Advanced Bionics, LLC ($3,381) |
| 2018 | $7,142 | 1 | Cochlear Ltd ($7,142) |
| 2017 | $254.51 | 3 | Advanced Bionics, LLC ($254.51) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $48.48 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $196.99 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 11/25/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $169.05 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 10/22/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $30.60 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 10/15/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $192.02 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 09/29/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $394.58 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 09/23/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $28.52 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $312.49 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $312.49 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 09/13/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $165.38 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 06/19/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $211.63 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $55.64 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 05/31/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $137.00 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 05/08/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $399.71 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 05/01/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $189.69 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 04/12/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $32.32 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 04/11/2024 | Advanced Bionics, LLC | HIRES ULTRA CI HIFOCUS MS ELECTRODE (Device) | Consulting Fee | Cash or cash equivalent | $1,060.00 | General |
| Category: OTOLARYNGOLOGY | ||||||
| 03/25/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $215.97 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 02/05/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $142.99 | General |
| 02/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $545.96 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 05/17/2023 | MED-EL Corporation | Mi1250 SYNCHRONY 2 FLEXsoft (Device), BCI 602 Kit | Food and Beverage | In-kind items and services | $150.86 | General |
| Category: Cochlear Implant | ||||||
| 03/01/2022 | Advanced Bionics, LLC | HIRES ULTRA CI HIFOCUS MS ELECTRODE (Device) | Travel and Lodging | Cash or cash equivalent | $435.40 | General |
| Category: OTOLARYNGOLOGY | ||||||
| 12/16/2019 | Advanced Bionics, LLC | HiResolution Bionic Ear System (Device) | Consulting Fee | Cash or cash equivalent | $2,650.00 | General |
| Category: OTOLARYNGOLOGY | ||||||
| 12/16/2019 | Advanced Bionics, LLC | HiResolution Bionic Ear System (Device) | Travel and Lodging | Cash or cash equivalent | $731.40 | General |
| Category: OTOLARYNGOLOGY | ||||||
| 04/14/2018 | Cochlear Ltd | Nucleus (Device), Baha | Travel and Lodging | Cash or cash equivalent | $7,141.86 | General |
| Category: Implantable hearing solution | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | Regeneron Pharmaceuticals, Inc. | $2,613 | 12 |
| A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | Regeneron Pharmaceuticals, Inc. | $1,026 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 288 | 317 | $57,980 | $16,056 |
| 2022 | 7 | 300 | 338 | $57,533 | $18,958 |
| 2021 | 7 | 323 | 363 | $59,753 | $20,584 |
| 2020 | 6 | 225 | 262 | $36,425 | $11,304 |
Total Patients
1,136
Total Services
1,280
Medicare Billing
$66,902
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 62 | 68 | $17,217 | $4,792 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 70 | 82 | $14,208 | $4,184 | 29.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 42 | 42 | $9,598 | $2,465 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 18 | $6,369 | $1,990 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 18 | 18 | $7,055 | $1,723 | 24.4% |
| 92504 | Exam of ear using a microscope | Facility | 2023 | 68 | 77 | $2,282 | $566.68 | 24.8% |
| 69210 | Removal of impacted ear wax | Facility | 2023 | 12 | 12 | $1,251 | $335.64 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 75 | 92 | $13,093 | $4,673 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 34 | 34 | $12,240 | $3,852 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 51 | $11,177 | $3,802 | 34.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 58 | 58 | $12,137 | $3,672 | 30.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 18 | 19 | $5,872 | $2,075 | 35.3% |
| 92504 | Exam of ear using a microscope | Facility | 2022 | 54 | 72 | $2,151 | $541.79 | 25.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 12 | 12 | $864.40 | $340.83 | 39.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 75 | $16,058 | $5,781 | 36.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 80 | 93 | $12,946 | $4,973 | 38.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 42 | 42 | $14,759 | $4,715 | 31.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 45 | 45 | $9,243 | $3,028 | 32.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 11 | $3,326 | $1,031 | 31.0% |
| 92504 | Diagnostic examination of ear and nose | Facility | 2021 | 66 | 83 | $2,440 | $651.20 | 26.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 12 | 14 | $981.40 | $405.34 | 41.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 35 | 35 | $11,233 | $3,521 | 31.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 50 | $10,100 | $3,302 | 32.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 57 | 68 | $8,588 | $2,605 | 30.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 17 | 17 | $3,054 | $960.78 | 31.5% |
About Jay Rubinstein
Jay Rubinstein is a Otolaryngology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790860518.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jay Rubinstein has received a total of $16,206 in payments from pharmaceutical and medical device companies, with $4,842 received in 2024. These payments were reported across 28 transactions from 4 companies. The most common payment nature is "Travel and Lodging" ($8,309).
As a Medicare-enrolled provider, Rubinstein has provided services to 1,136 Medicare beneficiaries, totaling 1,280 services with total Medicare billing of $66,902. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Otolaryngology
- Other Specialties Pediatric Otolaryngology
- Location Seattle, WA
- Active Since 10/27/2006
- Last Updated 02/12/2009
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1790860518
Products in Payments
- Nucleus (Device) $7,142
- HiResolution Bionic Ear System (Device) $3,636
- HIRES ULTRA CI HIFOCUS MS ELECTRODE (Device) $1,495
- Mi1250 SYNCHRONY 2 FLEXsoft (Device) $150.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Otolaryngology Doctors in Seattle
Dr. Ian Humphreys, D.o, D.O
Otolaryngology — Payments: $47,012
Otolaryngology $47,012
Sachin Gupta, Md, MD
Otolaryngology — Payments: $24,345
Otolaryngology $24,345
Dr. Craig Miller, M.d, M.D
Otolaryngology — Payments: $23,655
Otolaryngology $23,655
Dr. Matthew Old, Md, MD
Otolaryngology — Payments: $9,798
Otolaryngology $9,798
Dr. Sharon Cushing, M.d. Msc, M.D. MSC
Otolaryngology — Payments: $9,384
Otolaryngology $9,384
Jonathan Perkins
Otolaryngology — Payments: $5,400
Otolaryngology $5,400